Recombinant Anti-CD20 × Anti-CD3 Bispecific Antibody (CrossMab)
CAT#: CROSS-L025
Recombinant Anti-CD20 × Anti-CD3 Bispecific Antibody (CrossMab) has been generated by applying the Crossmab format to generate an IgG shaped entity that binds each ligand with one arm. This BsAb is capable of targeting the tumor and recruiting T effector cells via binding to the CD3 subunit of the T cell receptor complex. It was designed for the treatment of Non-Hodgkin`s lymphoma and other CD20+ B-cell malignancies.
Specifications
- Target
- CD20 & CD3
- Type
- CrossMab
- Species Reactivity
- Human
- Target 1
- CD20
- Host Species 1
- Mouse
- Target 2
- CD3
- Host Species 2
- Mouse
- Application
- FuncS, Promising therapeutic agent
- Related Disease
- Non-Hodgkin`s lymphoma and other CD20+ B-cell malignancies
Target
- Target 1
- CD20
- Gene ID
- 931
- UniProt ID
- A0A024R507
- Alternative Names
- MS4A1; membrane-spanning 4-domains, subfamily A, member 1; B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; B-lymphocyte antigen CD20; CD20 antigen; CD20 receptor; leukocyte surface antigen Leu-16; B-lymphocyte cell-surface antigen B1
- Target 2
- CD3
- Gene ID
- 916
- UniProt ID
- P07766
- Alternative Names
- CD3E; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3
Customer Review
There are currently no Customer reviews or questions for CROSS-L025. Click the button above to contact us or submit your feedback about this product.
Q&As
-
What is the mechanism of action for this bispecific antibody in research?
A: This product functions by bridging T cells and CD20-expressing tumor cells. One arm binds to the CD20 antigen on B cells, while the other binds to the CD3 subunit of the T cell receptor complex. This physical proximity activates the T cells to exert cytotoxic effects on the target tumor cells.
-
Does this antibody retain the structure of a standard IgG molecule?
A: Yes, this bispecific antibody is generated using CrossMab technology to create an IgG-shaped molecule. This design allows it to maintain structural similarities to natural antibodies, potentially offering better stability and pharmacokinetic properties in your research models compared to smaller antibody fragments.
View the frequently asked questions answered by Creative Biolabs Support.
Submit Your Publication
Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.
Downloadable Resources
Download resources about recombinant antibody development and antibody engineering to boost your research.
Datasheet
MSDS
COA
Certificate of Analysis LookupTo download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Popular Products

Application: Neut, ELISA, IF, IP, FuncS, FC, IHC

Application: WB, FC, IP, ELISA, Neut, FuncS, IF
-2.png)
Application: FuncS, IF, Neut, ELISA, FC, IP, ICC

Application: WB, FuncS, IF, Neut, ELISA, FC, IP

Application: WB, ELISA, IP, FC, FuncS, Neut, IF

Application: IF, IP, Neut, FuncS, ELISA, FC, ICC

Application: WB, ELISA, FC, IP, FuncS, IF, Neut

Application: IF, IP, Neut, FuncS, ELISA, FC, WB

Application: FC, IP, ELISA, Neut, FuncS, IF, WB

Application: WB, ELISA, FC, IP, FuncS, IF, Neut

Application: WB, Neut, FuncS

Application: Neut, ELISA, Inhib, ICC, WB
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.











